FUSIONCHIP Trademark

Trademark Overview


On Wednesday, May 14, 2003, a trademark application was filed for FUSIONCHIP with the United States Patent and Trademark Office. The USPTO has given the FUSIONCHIP trademark a serial number of 78249506. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, September 28, 2012. This trademark is owned by IPSOGEN. The FUSIONCHIP trademark is filed in the Pharmaceutical Products category with the following description:

Diagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Durkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell...

General Information


Serial Number78249506
Word MarkFUSIONCHIP
Filing DateWednesday, May 14, 2003
Status710 - CANCELLED - SECTION 8
Status DateFriday, September 28, 2012
Registration Number2928680
Registration DateTuesday, March 1, 2005
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 7, 2004

Trademark Statements


Goods and ServicesDiagnostic biological reagents for clinical or medical laboratory use or for determining gene translocations with partner genes which lead to neurological illness, muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Durkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lung neoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma; pharmaceutical preparations for treatment of muscular dystrophy, autism, schizophrenia, Down syndrome, leukemia, lymphoma, melanomas of soft parts, liposarcoma, Ewings sarcoma, neuroectodermal tumors, myelodysplastic syndromes, chondrosarcoma, desmoplastic small round cell tumor, rhabdomyosarcoma, non-Hodgkins lymphoma, myeloproliferative disorders, cogenital fibrosarcoma, nephromas, multiple myelomas, parathyroid ademnomes, parathyroid neoplasms, adenomas, lymphoproliferative disorders, plasma cell malignancies, Burkitt lymphoma, meningiomas, dermatofibrosarcoma protuberans, papillary carcinoma, cemento ossifying fibromas of the orbit, orbital neoplasms, ossifying fibromas, salivary gland neoplasms, pleomorphic adenomas, lipomas, hamartomas, uterine neoplasms, leiomyomas, osteosarcomas, cultured tumor cells, neuroblastomas, plasma cell granulomas, papillary renal cell carcinomas, kidney neoplasms, renal cell carcinomas, papillary carcinomas, follicular adenocarcinomas, endometrial neoplasms, follicular lymphomas, glioblastomas, splenic neoplasms, lungneoplasms, squamous cell carcinomas, giant cell fibroblastoma, Bednar tumors, giant cell carcinomas, skin neoplasms, lipoblastomas, ganglioneuroblastomas, breast neoplasms, hypereosinophilic syndrome, synovial sarcoma
Pseudo MarkFUSION CHIP

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, September 28, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIPSOGEN
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressMarseille 13008
FR

Party NameIPSOGEN
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMarseille 13008
FR

Party NameIPSOGEN
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMarseille 13008
FR

Trademark Events


Event DateEvent Description
Friday, September 28, 2012CANCELLED SEC. 8 (6-YR)
Tuesday, March 1, 2005REGISTERED-PRINCIPAL REGISTER
Tuesday, December 7, 2004PUBLISHED FOR OPPOSITION
Wednesday, November 17, 2004NOTICE OF PUBLICATION
Friday, October 1, 2004LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, September 27, 2004ASSIGNED TO LIE
Monday, September 27, 2004ASSIGNED TO LIE
Thursday, September 23, 2004APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 2, 2004AMENDMENT FROM APPLICANT ENTERED
Thursday, August 26, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 26, 2004Sec. 1(B) CLAIM DELETED
Thursday, August 26, 2004PAPER RECEIVED
Saturday, July 17, 2004LETTER OF SUSPENSION E-MAILED
Friday, June 4, 2004CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 4, 2004PAPER RECEIVED
Saturday, December 6, 2003NON-FINAL ACTION E-MAILED
Thursday, December 4, 2003ASSIGNED TO EXAMINER
Wednesday, July 23, 2003PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Wednesday, July 23, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 13, 2003CASE FILE IN TICRS
Wednesday, August 13, 2003CASE FILE IN TICRS
Wednesday, July 23, 2003PAPER RECEIVED